Trinity Biotech plc to Announce First Quarter 2010 Financial Results

* Reuters is not responsible for the content in this press release.

Thu Apr 22, 2010 6:15am EDT 

  DUBLIN, IRELAND, Apr 22 (MARKET WIRE) -- 
Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer
of diagnostic products for the point-of-care and clinical laboratory
markets, will report financial results for the first quarter of 2010 on
Tuesday, May 11, 2010. The Company has scheduled a conference call for
that same day, Tuesday, May 11, 2010 at 11:00 am EDT (4:00 pm BST) to
discuss the results of the quarter. 

    Interested parties can access the call by dialing:

    USA: 1-877-317-6789
 International: 1-412-317-6789
 Conference ID #:
440022

    A simultaneous webcast of the call can be accessed at:
http://www.videonewswire.com/event.asp?id=68423

    A replay of the call can be accessed until May 17, 2010 by dialing:

    USA: 1-877-344-7529
 International: 1-412-317-0088
 Conference ID #:
440022

    The webcast of the call will be available for 30 days at:

http://www.videonewswire.com/event.asp?id=68423

    About Trinity Biotech plc
 Trinity Biotech develops, acquires,
manufactures and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory segments
of the diagnostic market. The products are used to detect infectious
diseases and blood coagulation disorders, and to quantify the level of
Hemoglobin A1c and other chemistry parameters in serum, plasma and whole
blood. Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information please see the company's website:
http://www.trinitybiotech.com. 

    Forward-looking statements in this release are made pursuant to the "safe
harbor" provision of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that such forward-looking statements
involve risks and uncertainties including, but not limited to, the
results of research and development efforts, the effect of regulation by
the United States Food and Drug Administration and other agencies, the
impact of competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the Company's
periodic reports filed with the Securities and Exchange Commission.

    

Contact: 
Trinity Biotech plc 
Kevin Tansley 
(353)-1-2769800 
E-mail: kevin.tansley@trinitybiotech.com 

Lytham Partners LLC 
Joe Diaz, Joe Dorame, & Robert Blum
602-889-9700 

Copyright 2010, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.